Maze Therapeutics Inc (MAZE)

Maze Therapeutics shares surge after positive Phase 2 data for MZE829March 25, 2026 10:21 AM
IH Market News
Maze Therapeutics Inc. (NASDAQ:MAZE) reported a fourth-quarter loss of $0.65 per share on Wednesday, while also announcing encouraging results from a Phase 2 clinical trial of its lead drug candidate MZE829.The company’s shares jumped 22.18% in pre-market trading following the release of the trial update.The clinical-stage biopharmaceutical firm generated no revenue in the quarter ended December 31, 2025, unchanged from the same period a year earlier. For the full year 2025, Maze also reported no revenue, compared with $167.5 million in 2024, which had included a $150 million upfront payment tied to its licensing agreement with Shionogi & Co., Ltd.The sharp rise in the stock came after the company disclosed positive topline results from its Phase 2 HORIZON trial evaluating MZE829 in patients with APOL1-mediated kidney disease (AMKD).According to the company, the study showed a mean reduction in proteinuria of 35.6% after 12 weeks among a broad group of AMKD patients, with half of the participants achieving reductions greater than 30%. Based on these outcomes, Maze said it intends to move MZE829 into a pivotal clinical development program.“We are proud of the progress that Maze achieved in 2025 and have already carried our strong record of execution into the new year, as evidenced by today’s positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD,” said Jason Coloma, Ph.D., chief executive officer of Maze.Research and development spending increased to $27.6 million in the fourth quarter, up from $22.2 million in the same period a year earlier, largely reflecting higher clinical trial and manufacturing costs. For the full year, R&D expenses rose to $108.4 million, compared with $83.5 million in the previous year.General and administrative expenses also increased, reaching $10.5 million in the quarter, up from $7.5 million a year earlier.Maze ended 2025 with $360.0 million in cash, cash equivalents, and marketable securities, compared with $196.8 million at the end of 2024. The company said its current cash resources are expected to support operations through 2028.Maze Therapeutics stock price

Original: Maze Therapeutics shares surge after positive Phase 2 data for MZE829

Enliven Therapeutics shares jump 28% after Merck’s $6.7 billion Terns acquisition announcementMarch 25, 2026 10:05 AM
IH Market News
Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 28% on Wednesday following news that Merck (NYSE:MRK) plans to acquire oncology-focused Terns Pharmaceuticals in a $6.7 billion transaction. Maze Therapeutics (NASDAQ:MAZE) also moved higher, rising about 10%.Merck announced Wednesday that it will purchase clinical-stage oncology company Terns Pharmaceuticals for $53.00 per share in cash, valuing the company’s equity at roughly $6.7 billion. After accounting for cash on hand, the deal represents about $5.7 billion and reflects a premium of 31% to the stock’s 60-day volume-weighted average price and 42% to the 90-day average as of Tuesday.The transaction is centered on TERN-701, Terns’ lead drug candidate. The investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor is currently being evaluated in the Phase 1/2 CARDINAL trial for patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia who have previously received at least one TKI and experienced treatment failure, insufficient response, or intolerance. In March 2024, the U.S. Food and Drug Administration granted Orphan Drug Designation to TERN-701 for the treatment of CML.Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule inhibitors for cancer treatment. Its pipeline includes ELVN-001, a kinase inhibitor currently in a Phase 1 trial for adults with chronic myeloid leukemia, and ELVN-002, a central nervous system-penetrant, irreversible HER2 inhibitor being studied in a Phase 1 trial for non-small cell lung cancer and other HER2-mutant tumors.Maze Therapeutics is also a clinical-stage biotechnology company developing precision small-molecule therapies targeting renal and cardiovascular diseases, as well as related metabolic conditions and obesity.Enliven Therapeutics stock price

Original: Enliven Therapeutics shares jump 28% after Merck’s $6.7 billion Terns acquisition announcement

MAZE reports Friday 6/20